ArticleJournal of market access & health policy2022

Cost comparison of adverse event management among breast and ovarian cancer patients treated with poly (ADP-ribose) polymerase inhibitors: analysis based on phase 3 clinical trials.

Lin Fan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.